Literature DB >> 19501187

Accumulation and persistence of Pig-A mutant peripheral red blood cells following treatment of rats with single and split doses of N-ethyl-N-nitrosourea.

Daishiro Miura1, Vasily N Dobrovolsky, Takafumi Kimoto, Yoshinori Kasahara, Robert H Heflich.   

Abstract

We previously reported the development of an in vivo gene mutation assay using the phosphatidylinositol glycan complementation group A gene (Pig-A) as an endogenous reporter. The assay quantifies mutation in rat peripheral red blood cells (RBCs) by flow cytometric detection of cells negative for glycosylphosphatidyl inositol (GPI)-anchored protein surface markers. In this study, we examined the accumulation and persistence of Pig-A mutant RBCs in rats treated with N-ethyl-N-nitrosourea (ENU) using two dosing schedules. Male F344 rats were given single i.p. injections of 8.9, 35.6, or 142.4 mg/kg ENU or four equal weekly doses totaling 35.6 or 142.4 mg/kg ENU (8.9 mg/kgx4 or 35.6 mg/kgx4; split-dose groups). Before the treatment and through 26 weeks after the single dose or beginning the split-dose regimen, peripheral RBCs were collected and Pig-A mutant frequencies measured as RBCs negative for the GPI-anchored protein, CD59. Mean CD59-negative RBC frequencies in negative control rats ranged from 3.9 x 10(-6) to 28.7 x 10(-6) and displayed no time-related trend. With single ENU doses, CD59-negative RBC frequencies increased in a time- and dose-related manner. Maximum responses were observed beginning at 6 weeks post-treatment (57.3 x 10(-6) in the 8.9 mg/kg group; 186.9 x 10(-6) in the 35.6 mg/kg group; 759.2 x 10(-6) in the 142.4 mg/kg group), and these elevated mutant frequencies persisted to the last sampling time. In addition, splitting the dose of ENU into four weekly doses produced nearly the same mutant frequency as when given as a single dose: the maximum responses after four weekly doses of 8.9 or 35.6 mg/kg were 176.8 x 10(-6) and 683.3 x 10(-6), respectively. These results indicate that ENU-induced Pig-A mutant RBCs accumulate in a near additive fashion in rats, and once present in the peripheral blood, persist for at least 6 months. These characteristics of Pig-A mutation could be important for detecting weak mutagens by repeated or subchronic/chronic dosing protocols.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19501187     DOI: 10.1016/j.mrgentox.2009.05.014

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  11 in total

1.  When pigs fly: immunomagnetic separation facilitates rapid determination of Pig-a mutant frequency by flow cytometric analysis.

Authors:  Stephen D Dertinger; Steven M Bryce; Souk Phonethepswath; Svetlana L Avlasevich
Journal:  Mutat Res       Date:  2011-01-28       Impact factor: 2.433

2.  Integration of Pig-a, micronucleus, chromosome aberration and comet assay endpoints in a 28-day rodent toxicity study with urethane.

Authors:  Leon F Stankowski; Marilyn J Aardema; Timothy E Lawlor; Kamala Pant; Shambhu Roy; Yong Xu; Reem Elbekai
Journal:  Mutagenesis       Date:  2015-05-01       Impact factor: 3.000

3.  Defining EMS and ENU dose-response relationships using the Pig-a mutation assay in rats.

Authors:  Krista L Dobo; Ronald D Fiedler; William C Gunther; Catherine J Thiffeault; Zoryana Cammerer; Stephanie L Coffing; Thomas Shutsky; Maik Schuler
Journal:  Mutat Res       Date:  2011-06-24       Impact factor: 2.433

4.  Integration of mutation and chromosomal damage endpoints into 28-day repeat dose toxicology studies.

Authors:  Stephen D Dertinger; Souk Phonethepswath; Dean Franklin; Pamela Weller; Dorothea K Torous; Steven M Bryce; Svetlana Avlasevich; Jeffrey C Bemis; Ollivier Hyrien; James Palis; James T MacGregor
Journal:  Toxicol Sci       Date:  2010-03-04       Impact factor: 4.849

5.  Persistence of cisplatin-induced mutagenicity in hematopoietic stem cells: implications for secondary cancer risk following chemotherapy.

Authors:  Stephen D Dertinger; Svetlana L Avlasevich; Dorothea K Torous; Jeffrey C Bemis; Souk Phonethepswath; Carson Labash; Kristine Carlson; Jared Mereness; John Cottom; James Palis; James T MacGregor
Journal:  Toxicol Sci       Date:  2014-05-05       Impact factor: 4.849

6.  Pig-a mutation: kinetics in rat erythrocytes following exposure to five prototypical mutagens.

Authors:  Souk Phonethepswath; Dean Franklin; Dorothea K Torous; Steven M Bryce; Jeffrey C Bemis; Sarojini Raja; Svetlana Avlasevich; Pamela Weller; Ollivier Hyrien; James Palis; James T Macgregor; Stephen D Dertinger
Journal:  Toxicol Sci       Date:  2009-12-04       Impact factor: 4.849

7.  Sensitivity of the Pig-a assay for detecting gene mutation in rats exposed acutely to strong clastogens.

Authors:  Javed A Bhalli; Joseph G Shaddock; Mason G Pearce; Vasily N Dobrovolsky
Journal:  Mutagenesis       Date:  2013-05-15       Impact factor: 3.000

8.  Efficient monitoring of in vivo pig-a gene mutation and chromosomal damage: summary of 7 published studies and results from 11 new reference compounds.

Authors:  Stephen D Dertinger; Souk Phonethepswath; Svetlana L Avlasevich; Dorothea K Torous; Jared Mereness; Steven M Bryce; Jeffrey C Bemis; Sara Bell; Pamela Weller; James T Macgregor
Journal:  Toxicol Sci       Date:  2012-08-24       Impact factor: 4.849

9.  Single cell gel electrophoresis (SCGE) and Pig-a mutation assay in vivo-tools for genotoxicity testing from a regulatory perspective: a study of benzo[a]pyrene in Ogg1(-/-) mice.

Authors:  Anne Graupner; Christine Instanes; Stephen D Dertinger; Jill Mari Andersen; Birgitte Lindeman; Tonje Danielsen Rongved; Gunnar Brunborg; Ann-Karin Olsen
Journal:  Mutat Res Genet Toxicol Environ Mutagen       Date:  2014-08-07       Impact factor: 2.873

10.  Absence of in vivo mutagenicity of multi-walled carbon nanotubes in single intratracheal instillation study using F344 gpt delta rats.

Authors:  Katsuyoshi Horibata; Akiko Ukai; Akio Ogata; Dai Nakae; Hiroshi Ando; Yoshikazu Kubo; Akemichi Nagasawa; Katsuhiro Yuzawa; Masamitsu Honma
Journal:  Genes Environ       Date:  2017-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.